Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ophthalmology

Free Subscription Articles published in J Ocul Pharmacol Ther Retrieve available abstracts of 122 articles: HTML format

Single Articles

September 2025
1. DMUCHOWSKA DA, Godzien J, Mojsak P, Godlewski A, et al
   Comment on: Changes in Aqueous Humor Cytokines and Metabolomics in Contralateral Eye After Unilateral Cataract Surgery.
   J Ocul Pharmacol Ther. 2025 Sep 19. doi: 10.1177/10807683251380991.
   PubMed     Abstract available
   
   
   
2. RASSI TNO, Amaral DC, Mund E, Pimentel ALM, et al
   Assessing Long-Term Feasibility and Efficacy of Treatments for Retinal Vein Occlusion Macular Edema: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
   J Ocul Pharmacol Ther. 2025 Sep 18. doi: 10.1177/10807683251380974.
   PubMed     Abstract available
   
   
   
3. ZENG F, He H, Huang S, Luo Y, et al
   Brimonidine Topical Eye Drops and Intravitreal Administration Inhibit Form-Deprivation Myopia in Guinea Pigs: Ocular Pharmacokinetics and Irritation.
   J Ocul Pharmacol Ther. 2025 Sep 18. doi: 10.1177/10807683251376438.
   PubMed     Abstract available
   
   
   
4. LEE H, Sharma A, Woo SJ
   Clinical Trials of Aflibercept Biosimilars: A Review.
   J Ocul Pharmacol Ther. 2025;41:363-369.
   PubMed     Abstract available
   
   
   
5. KHOLZODA S, Ozkan G, Dericioglu V, Akkaya Turhan S, et al
   Topical Cyclosporine and Steroid Treatments: A Comparative Approach to Membranous Punctal Stenosis.
   J Ocul Pharmacol Ther. 2025;41:387-396.
   PubMed     Abstract available
   
   
   August 2025
6. YILDIRIM H, Balbaba M, Canleblebici M, Dal A, et al
   Effect of Dasatinib on Oxidative Stress and Neovascularization in Experimental Corneal Neovascularization.
   J Ocul Pharmacol Ther. 2025 Aug 21. doi: 10.1177/10807683251370551.
   PubMed     Abstract available
   
   
   
7. FEKI O, Zhioua-Braham I, Haddar S, Arfaoui A, et al
   The Endocannabinoid System: Role in Ocular Physiology and Therapeutic Potential in Eye Diseases: A Narrative Review.
   J Ocul Pharmacol Ther. 2025 Aug 21. doi: 10.1177/10807683251368650.
   PubMed     Abstract available
   
   
   
8. SHEN M, Xu B
   Rosmarinic Acid Mitigates Lipopolysaccharide-Induced Inflammation and Oxidative Stress in Human Corneal Epithelial Cells as an In Vitro Keratitis Cell Model.
   J Ocul Pharmacol Ther. 2025 Aug 15. doi: 10.1177/10807683251366780.
   PubMed     Abstract available
   
   
   
9. NORK TM, Katz AW, Rasmussen CA, Kim CBY, et al
   Custom-Made Injector for Suprachoroidal Ocular Delivery: Effect of Intraocular Pressure, Volume, and Location on the Distribution of Aqueous Solutions in Rabbits.
   J Ocul Pharmacol Ther. 2025 Aug 8. doi: 10.1177/10807683251366799.
   PubMed     Abstract available
   
   
   
10. LEI J, Zeng L, Gao X, Wang D, et al
    Comparison of Topical Gatifloxacin and Levofloxacin at Different Durations in Eliminating Conjunctival Bacterial Flora.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1177/10807683251366114.
    PubMed     Abstract available
    
    
    
11. XIA R, Lin L, Liu Z, Chen W, et al
    Nonsurgical Therapies for Preventing Corneal Scarring: A Systematic Review of the Past Decade.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1177/10807683251361725.
    PubMed     Abstract available
    
    
    
12. KHAN H, Aftab OM, Billah MS, Khouri AS, et al
    Beyond the Prostate: A Visionary Study on Ocular Impacts of Benign Prostatic Hyperplasia Drugs.
    J Ocul Pharmacol Ther. 2025 Aug 6. doi: 10.1089/jop.2025.0030.
    PubMed     Abstract available
    
    
    
13. WANG Z, Li G, Lu H, Wang J, et al
    The Efficacy and Safety of Tumor Necrosis Factor alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Aug 5. doi: 10.1177/10807683251363436.
    PubMed     Abstract available
    
    
    
14. MONTMEAT D, Thouvenin A, Rasamison R, Boudy V, et al
    Physicochemical Properties and Rheological Behavior of Artificial Tears for Dry Eye Syndrome.
    J Ocul Pharmacol Ther. 2025 Aug 5. doi: 10.1177/10807683251364169.
    PubMed     Abstract available
    
    
    
15. CHOUDHRY HS, Pei M, Mothy D, Scarfuto J, et al
    Real-World Safety Profile of Cenegermin Per FDA Adverse Event Reporting System.
    J Ocul Pharmacol Ther. 2025;41:339-346.
    PubMed     Abstract available
    
    
    July 2025
16. ROJAS R, Hinkle DM
    Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse Events.
    J Ocul Pharmacol Ther. 2025 Jul 30. doi: 10.1177/10807683251363420.
    PubMed    
    
    
    
17. HERBOTS H, Van Os L, Aerts W, Tassignon MJ, et al
    Evaluation of Systemic Exposure to Intracameral Tropicamide 0.02%, Phenylephrine 0.31%, and Lidocaine 1% in Pediatric Cataract Surgery.
    J Ocul Pharmacol Ther. 2025 Jul 18. doi: 10.1177/10807683251359451.
    PubMed     Abstract available
    
    
    
18. ZHOU J, Wang D, Li GC, Huang Q, et al
    GCN5-TFEB Pathway Regulates Inflammation by Tuning Autophagic Degradation of Retinoic Acid-Induced Gene-I in Human Conjunctival Epithelial Cells.
    J Ocul Pharmacol Ther. 2025 Jul 9. doi: 10.1089/jop.2025.0029.
    PubMed     Abstract available
    
    
    June 2025
19. SUN N, Hu X, Wang J, Yao T, et al
    Minichromosome Maintenance Complex Genes Are Candidate Biomarkers of Retinal Degeneration.
    J Ocul Pharmacol Ther. 2025 Jun 27. doi: 10.1089/jop.2025.0047.
    PubMed     Abstract available
    
    
    
20. WANG Q, Peng Y, Wang S, Xu J, et al
    Exploring the Efficacy of AZD6738 in Corneal Neovascularization: Autophagy Enhancement and Angiogenesis Inhibition.
    J Ocul Pharmacol Ther. 2025 Jun 27. doi: 10.1089/jop.2024.0162.
    PubMed     Abstract available
    
    
    
21. SRIKAJORN C, Tiyaboonchai W, Srinivas SP, Thongsuk W, et al
    Mucoadhesive Silk Fibroin Nanoparticles for Drug Delivery to the Ocular Surface.
    J Ocul Pharmacol Ther. 2025 Jun 24. doi: 10.1089/jop.2024.0180.
    PubMed     Abstract available
    
    
    
22. KROSSER S, Grillenberger R, Eickhoff K, Korward J, et al
    Ocular Pharmacokinetics and Biodistribution of Perfluorohexyloctane after Topical Administration to Rabbits.
    J Ocul Pharmacol Ther. 2025 Jun 19. doi: 10.1089/jop.2025.0056.
    PubMed     Abstract available
    
    
    
23. OZGUR A, Ozmen MC, Yalinbas Yeter D, Inan MA, et al
    Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study.
    J Ocul Pharmacol Ther. 2025 Jun 11. doi: 10.1089/jop.2025.0068.
    PubMed     Abstract available
    
    
    
24. CHU G, Wang J, Wang Z, Cai X, et al
    Autologous Serum from Sjogren's Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy.
    J Ocul Pharmacol Ther. 2025 Jun 11. doi: 10.1089/jop.2025.0025.
    PubMed     Abstract available
    
    
    
25. PADMANABHAN NAIR A, Machiraju P, Tejwani S, Dinakaran S, et al
    Lower Levels of Endogenous Intraocular Interferon Beta in Patients with Primary Glaucoma.
    J Ocul Pharmacol Ther. 2025 Jun 9. doi: 10.1089/jop.2025.0085.
    PubMed     Abstract available
    
    
    
26. SUN CC, Pan LY, Chen NN, Kuo YK, et al
    Risk and Protective Factors for Ocular Surface Disease in Patients with Type 2 Diabetic Mellitus: A Retrospective Cohort Study.
    J Ocul Pharmacol Ther. 2025 Jun 9. doi: 10.1089/jop.2024.0175.
    PubMed     Abstract available
    
    
    
27. SADRI E, Verachtert A, Parkhurst GD, Echegoyen J, et al
    Durability of Treatment with a Thermomechanical Device in Meibomian Gland Dysfunction: An Observational Extension Study.
    J Ocul Pharmacol Ther. 2025;41:237-243.
    PubMed     Abstract available
    
    
    
28. DOLAN K
    Rosalind Franklin Society Proudly Announces the 2024 Award Recipient for Journal of Ocular Pharmacology and Therapeutics.
    J Ocul Pharmacol Ther. 2025;41:229.
    PubMed    
    
    
    May 2025
29. ROY A, Kompella UB
    Rose Bengal-Assisted Photodynamic Antimicrobial Therapy for Keratitis.
    J Ocul Pharmacol Ther. 2025 May 29. doi: 10.1089/jop.2025.0010.
    PubMed     Abstract available
    
    
    
30. LACAU S, Marin A, Bitrian E
    Steroid-Induced Ocular Hypertension in Children: A Review on Risk Factors.
    J Ocul Pharmacol Ther. 2025 May 13. doi: 10.1089/jop.2025.0024.
    PubMed     Abstract available
    
    
    
31. AFTAB OM, Khan H, Aftab B, Haque W, et al
    Corneal Complications: Drug-Induced Deposits and Food and Drug Administration Adverse Event Reporting System Data Insights-A Retrospective Study.
    J Ocul Pharmacol Ther. 2025 May 5. doi: 10.1089/jop.2024.0178.
    PubMed     Abstract available
    
    
    
32. SHARMA A, Sharma PK, Kompella UB
    Lotilaner for Demodex Blepharitis: The Journey from Veterinary Use to Human Medicine.
    J Ocul Pharmacol Ther. 2025;41:173-186.
    PubMed     Abstract available
    
    
    
33. NAVARRO-NARANJO PI, Chacon-Aponte A, Artunduaga-Rodriguez G
    Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease.
    J Ocul Pharmacol Ther. 2025;41:210-216.
    PubMed     Abstract available
    
    
    April 2025
34. FAHMY A, Ahmed M, Pflugfelder S, Serikbaeva A, et al
    Comparative Efficacy of Current Topical Treatments for Dry Eye Disease: A Review of Pivotal Clinical Trials Evaluating Corneal Staining Outcomes.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0192.
    PubMed     Abstract available
    
    
    
35. LIU J, Jiang E, Kim H, Moon J, et al
    Beneficial Effect of Rebamipide Eye Drops on Blue Light-Induced Oxidative Damage in the Ocular Surface.
    J Ocul Pharmacol Ther. 2025 Apr 28. doi: 10.1089/jop.2024.0208.
    PubMed     Abstract available
    
    
    
36. SANCHEZ-TOCINO H, Villanueva Gomez A, Saldana Burgos R, Hata Viveiros MM, et al
    Myopia Progression Study Comparing Low-Dose (0.01%) Atropine Eye Drops with a Control Group.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0202.
    PubMed     Abstract available
    
    
    
37. QUIRKE M, Lamoureux F, Arnoult C, Gress G, et al
    Tacrolimus 0.1% Ophthalmic Suspension: Corneal and Intraocular Penetration Study.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0165.
    PubMed     Abstract available
    
    
    
38. PETTY RM, Rangan RS, Curry S, Brooks CD, et al
    Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.
    J Ocul Pharmacol Ther. 2025 Apr 18. doi: 10.1089/jop.2024.0191.
    PubMed     Abstract available
    
    
    
39. DUTRA BAL, Wilson SE
    Topical Losartan in the Management of Corneal Scarring Fibrosis: Update on Dosage, Efficacy, and Potential Epithelial Toxicity.
    J Ocul Pharmacol Ther. 2025 Apr 16. doi: 10.1089/jop.2024.0200.
    PubMed     Abstract available
    
    
    
40. REITINGER JC, Reed DM, Peres C, Fan S, et al
    Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.
    J Ocul Pharmacol Ther. 2025 Apr 14. doi: 10.1089/jop.2024.0112.
    PubMed     Abstract available
    
    
    
41. JIN H, Yoon HJ, Jiang E, Liu J, et al
    Therapeutic Effects of Human Placental Extracts Eye Drops in Experimental Dry Eye and Alkali Burn.
    J Ocul Pharmacol Ther. 2025;41:141-149.
    PubMed     Abstract available
    
    
    March 2025
42. KISHI A, Bryant AD, Reed DM, Toris CB, et al
    Letter to the Editor: Effect of Aqueous Tears on Topical Fluorescein Tracer Emission Signal from Cornea and Anterior Chamber.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0143.
    PubMed    
    
    
    
43. PUTRI LR, Edwar L
    Corticosteroid as Treatment in Infective Conjunctivitis: A Systematic Literature Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Mar 10. doi: 10.1089/jop.2024.0110.
    PubMed     Abstract available
    
    
    
44. AFTAB OM, Khan H, Bargoud A, Khouri AS, et al
    Are Alpha-2 Adrenergic Agonists Being Used in Infants?
    J Ocul Pharmacol Ther. 2025;41:75-78.
    PubMed     Abstract available
    
    
    February 2025
45. ROUTH BL, Tripathi R, Giuliano EA, Lankau BR, et al
    Effect of Chemical Injury on Autophagy in Canine Corneal Stromal Fibroblasts.
    J Ocul Pharmacol Ther. 2025 Feb 17. doi: 10.1089/jop.2024.0211.
    PubMed     Abstract available
    
    
    
46. ALEKSANDER-IVANOV Y, Amaral DC, Cheidde L, Lima GN, et al
    Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    J Ocul Pharmacol Ther. 2025 Feb 10. doi: 10.1089/jop.2024.0169.
    PubMed     Abstract available
    
    
    
47. VOUGHT R, Vought V, Crane AB, Khouri AS, et al
    Medicare Part D Glaucoma Drug Prescribing Patterns by Ophthalmologists from 2018 to 2022.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0196.
    PubMed     Abstract available
    
    
    
48. HONG S, Woo M, Eom Y, Kim HK, et al
    A Multicenter, Randomized, Clinical Trial Assessing the Effect of rTG-Omega 3 Supplementation on Meibomian Gland Dysfunction Patients after Cataract Surgery rTG-Omega 3 for Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2025 Feb 5. doi: 10.1089/jop.2024.0160.
    PubMed     Abstract available
    
    
    
49. SADIKAN MZ, Lambuk L, Reshidan NH, Abdul Ghani NA, et al
    Age-Related Macular Degeneration Pathophysiology and Therapeutic Potential of Tocotrienols: An Update.
    J Ocul Pharmacol Ther. 2025 Feb 3. doi: 10.1089/jop.2024.0123.
    PubMed     Abstract available
    
    
    January 2025
50. COSKUN A, Senturk F, Turan E
    Enhanced Transepithelial Riboflavin Delivery Across the Cornea Using Magnetic Nanocarriers.
    J Ocul Pharmacol Ther. 2025 Jan 30. doi: 10.1089/jop.2024.0183.
    PubMed     Abstract available
    
    
    
51. SARKAR T, Gogoi NR, Jana BK, Mazumder B, et al
    Formulation Advances in Posterior Segment Ocular Drug Delivery.
    J Ocul Pharmacol Ther. 2025 Jan 23. doi: 10.1089/jop.2024.0153.
    PubMed     Abstract available
    
    
    
52. CRUZ MRB, Amaral DC, Goncalves OR, Cyrino LG, et al
    Chlorhexidine Compared with Povidone-Iodine in Intravitreal Injection: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2025 Jan 21. doi: 10.1089/jop.2024.0141.
    PubMed     Abstract available
    
    
    
53. GRESS G, Lamoureux F, Bourgain J, Ganem A, et al
    Selective Tissue Penetration of the Corneal Layers of Cyclosporin 2% Associated with Miglyol in Rabbits.
    J Ocul Pharmacol Ther. 2025 Jan 20. doi: 10.1089/jop.2024.0087.
    PubMed     Abstract available
    
    
    
54. SADIKAN MZ, Lambuk L, Reshidan N, Ahmad Hairi H, et al
    Molecular Mechanisms of Vitamin E in Ocular Neurodegenerative Disorders: An Update on the Emerging Evidence and Therapeutic Implications.
    J Ocul Pharmacol Ther. 2025 Jan 8. doi: 10.1089/jop.2024.0125.
    PubMed     Abstract available
    
    
    
55. HOARAU G, Best AL, Zina-Meziou S, Benali-Abdallah M, et al
    Effects of Intense Pulsed Light on Presumed Neuropathic Pain Associated with Meibomian Gland Dysfunction: A Before-After Study.
    J Ocul Pharmacol Ther. 2025;41:24-32.
    PubMed     Abstract available
    
    
    December 2024
56. IRFAN AMSM, Geoffrey S, Htet H, Krishnappa P, et al
    N-Methyl-d-Aspartate-Induced Excitotoxicity and Its Impact on the Renin-Angiotensin System in Retinal Tissue.
    J Ocul Pharmacol Ther. 2024 Dec 13. doi: 10.1089/jop.2024.0131.
    PubMed     Abstract available
    
    
    
57. KOVALIS N, Graffi S, Safuri S, Shapira Y, et al
    Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.
    J Ocul Pharmacol Ther. 2024;40:675-679.
    PubMed     Abstract available
    
    
    
58. YAN YL, Chang JY, Ling XR, Xue CY, et al
    Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2024;40:629-637.
    PubMed     Abstract available
    
    
    
59. WANG N, Yuan K, Yang S, Jin X, et al
    13-cis Retinoic Acid-Mediated Modulation of Human Meibomian Gland Epithelial Cells Development: Implications for In Vitro Modeling of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:659-667.
    PubMed     Abstract available
    
    
    
60. BHUJBAL S, Rupenthal ID, Steven P, Agarwal P, et al
    Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments.
    J Ocul Pharmacol Ther. 2024;40:638-658.
    PubMed     Abstract available
    
    
    
61. SEETHARAMAN ATM, Owens CE, Gangaraju R
    Cysteinyl Leukotriene Receptor Antagonism by Montelukast to Treat Visual Deficits.
    J Ocul Pharmacol Ther. 2024;40:617-628.
    PubMed     Abstract available
    
    
    November 2024
62. ERB C, Topouzis F, Jayaram H, Allan F, et al
    Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension.
    J Ocul Pharmacol Ther. 2024 Nov 7. doi: 10.1089/jop.2024.0092.
    PubMed     Abstract available
    
    
    
63. ROWE-RENDLEMAN CL
    Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1.
    J Ocul Pharmacol Ther. 2024 Nov 4. doi: 10.1089/jop.2024.0151.
    PubMed    
    
    
    
64. NGUYEN A, Naidoo KK, Ajouz L, Xu X, et al
    Changes in Human Meibum Lipid Composition Related to the Presence and Severity of Meibomian Gland Dysfunction.
    J Ocul Pharmacol Ther. 2024;40:562-570.
    PubMed     Abstract available
    
    
    October 2024
65. HWANG JS, Song HB, Lee G, Jeong S, et al
    Extracellular Vesicles Derived from Adipose-Derived Mesenchymal Stem Cells Alleviate Apoptosis and Oxidative Stress of Retinal Pigment Epithelial Cells Through Activation of Nrf2 Signaling Pathway.
    J Ocul Pharmacol Ther. 2024 Oct 25. doi: 10.1089/jop.2024.0064.
    PubMed     Abstract available
    
    
    
66. DIBAS A, Batabyal S, Kim S, Carlson M, et al
    Efficacy of Intravitreal Multi-Characteristic Opsin (MCO-010) Optogenetic Gene Therapy in a Mouse Model of Leber Congenital Amaurosis.
    J Ocul Pharmacol Ther. 2024 Oct 23. doi: 10.1089/jop.2024.0084.
    PubMed     Abstract available
    
    
    
67. BOUHAJIB M, Tayab Z, Di Marco C, Suh DD, et al
    Clinical Pharmacokinetics of Atropine Administered Ocularly Using an Ultrasensitive Bioanalytical Assay.
    J Ocul Pharmacol Ther. 2024 Oct 4. doi: 10.1089/jop.2024.0113.
    PubMed     Abstract available
    
    
    
68. SULTAN A, Harris DL, Lam P, Whitcomb J, et al
    The Optejet Technology Minimizes Preservative-Mediated Cytotoxicity of Conjunctival Epithelial Cells Treated with Latanoprost In Vitro.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0085.
    PubMed     Abstract available
    
    
    
69. HILL M, Andrews-Pfannkoch C, Atherton E, Knudsen T, et al
    Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0130.
    PubMed     Abstract available
    
    
    
70. MATSUMOTO R, Obata S, Kakinoki M, Sawada O, et al
    Duration of Vascular Endothelial Growth Factor Suppression after Intravitreal Injection of Faricimab in Macaque Eyes.
    J Ocul Pharmacol Ther. 2024 Oct 2. doi: 10.1089/jop.2024.0138.
    PubMed     Abstract available
    
    
    September 2024
71. JUAN HY, Sheu SJ, Hwang DK
    Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis.
    J Ocul Pharmacol Ther. 2024 Sep 24. doi: 10.1089/jop.2024.0100.
    PubMed     Abstract available
    
    
    
72. LUHAR M, Viradiya R, Panjabi S, Patel G, et al
    Nanotechnology in Ocular Drug Delivery: The Potential of Polymeric Micelles as a Drug Delivery Vehicle.
    J Ocul Pharmacol Ther. 2024 Sep 12. doi: 10.1089/jop.2024.0060.
    PubMed    
    
    
    
73. TSENG KA
    Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Journal of Ocular Pharmacology and Therapeutics.
    J Ocul Pharmacol Ther. 2024;40:407.
    PubMed    
    
    
    
74. FUKUDA M, Kiyoi T, Takeda S, Sasaki Y, et al
    Preventative Effect of Topical Rebamipide Against Corneal Epithelium Disorders Caused by Diclofenac Sodium.
    J Ocul Pharmacol Ther. 2024;40:428-434.
    PubMed     Abstract available
    
    
    
75. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:408-409.
    PubMed    
    
    
    
76. ZHAO Y, Zhang X, Zhou X, Chen B, et al
    IL-22/IL-22RA1 Promotes Human Tenon's Capsule Fibroblasts Proliferation and Regulates Fibrosis Through STAT3 Signaling Pathway.
    J Ocul Pharmacol Ther. 2024;40:435-444.
    PubMed     Abstract available
    
    
    August 2024
77. GAO AY, Whaley MG, Saraf N, Bakri SJ, et al
    Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics.
    J Ocul Pharmacol Ther. 2024 Aug 29. doi: 10.1089/jop.2024.0006.
    PubMed     Abstract available
    
    
    
78. DURRANI AF, Momenaei B, Soni V, Tennant M, et al
    Long-Term Stability, Sterility, And Cost-Effectiveness of 0.05% Chlorhexidine Gluconate as Antisepsis for Intravitreal Injection.
    J Ocul Pharmacol Ther. 2024 Aug 22. doi: 10.1089/jop.2024.0071.
    PubMed     Abstract available
    
    
    
79. BACHARACH J, McLaurin EB, Silverstein S, Amrane M, et al
    Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.
    J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0029.
    PubMed     Abstract available
    
    
    
80. CREAN CS, Yeu E, Maiti S, Neervannan S, et al
    Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.
    J Ocul Pharmacol Ther. 2024 Aug 16. doi: 10.1089/jop.2024.0074.
    PubMed     Abstract available
    
    
    July 2024
81. WON J, Kang J, Kang W
    Comparative Ocular Pharmacokinetics of Dexamethasone Implants in Rabbits.
    J Ocul Pharmacol Ther. 2024 Jul 24. doi: 10.1089/jop.2024.0052.
    PubMed    
    
    
    
82. HAMEED SS, Bodi NE, Miller RC, Sharma TP, et al
    Neuritin 1 Drives Therapeutic Preservation of Retinal Ganglion Cells in an Ex Vivo Human Glaucoma Model.
    J Ocul Pharmacol Ther. 2024 Jul 12. doi: 10.1089/jop.2024.0041.
    PubMed     Abstract available
    
    
    
83. ZEMITIS A, Vanags J, Fan J, Klavins K, et al
    Metabolomic Disparities in Intraocular Fluid Across Varied Stages of Cataract Progression: Implications for the Analysis of Cataract Development.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0067.
    PubMed     Abstract available
    
    
    
84. CHAUVIER J, Trone MC, Gain P, Ollier E, et al
    Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0023.
    PubMed     Abstract available
    
    
    
85. KASHIKAR R, Senapati S, Dudhipala N, Basu SK, et al
    Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0055.
    PubMed     Abstract available
    
    
    
86. DOLAN K, Liao SM, Crowley M, Xiang C, et al
    Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0046.
    PubMed     Abstract available
    
    
    
87. ZOR KR, Yilmaz U, Bozkurt SB
    Coenzyme Q10 and Vitamin E Regulate the Bioactivity of Human Corneal Fibroblast Cells.
    J Ocul Pharmacol Ther. 2024 Jul 8. doi: 10.1089/jop.2024.0050.
    PubMed     Abstract available
    
    
    
88. MENG C, Wei Q, Gu C, He S, et al
    Prevalence and Risk Factors of Ocular Demodex at Ultra-High Altitude and Sea Level: A Cross-Sectional Study of Shigatse and Shanghai.
    J Ocul Pharmacol Ther. 2024 Jul 4. doi: 10.1089/jop.2024.0038.
    PubMed     Abstract available
    
    
    
89. PAGNACCO C, Tosi R, Dalsaso J, Fraccaroli S, et al
    A Prospective, Randomized, Controlled Clinical Investigation Comparing the Efficacy and Safety of Sodium Hyaluronate-Based Ophthalmical Viscosurgical Devices FIDIAL PLUS and IAL((R))-F in Cataract Surgery.
    J Ocul Pharmacol Ther. 2024 Jul 1. doi: 10.1089/jop.2024.0044.
    PubMed     Abstract available
    
    
    
90. YAO Q, Wu H, Ren H, Cao J, et al
    Inhibition of Experimental Corneal Neovascularization by the Tight Junction Protein ZO-1.
    J Ocul Pharmacol Ther. 2024;40:379-388.
    PubMed     Abstract available
    
    
    
91. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:325-326.
    PubMed    
    
    
    
92. MICHAEL E, Singh V
    Diagnostic Uses of Common Eye Drops.
    J Ocul Pharmacol Ther. 2024;40:327-331.
    PubMed     Abstract available
    
    
    June 2024
93. KLEINMAN D, Iqbal S, Ghosh AK, Ogle SD, et al
    PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro.
    J Ocul Pharmacol Ther. 2024 Jun 27. doi: 10.1089/jop.2024.0019.
    PubMed     Abstract available
    
    
    
94. VARDAR C, George-Weinstein M, Getts R, Byrne ME, et al
    Evaluation of Dose-Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts.
    J Ocul Pharmacol Ther. 2024 Jun 20. doi: 10.1089/jop.2024.0024.
    PubMed     Abstract available
    
    
    
95. LIU L, Wang S, Blanco T, Ge H, et al
    Neurokinin-1 Receptor Antagonism Reduces Nonallergic Ocular Redness in a Rabbit Model.
    J Ocul Pharmacol Ther. 2024 Jun 3. doi: 10.1089/jop.2024.0003.
    PubMed     Abstract available
    
    
    
96. LEE SS, Nagar S, Rajagopalan L, Orilla W, et al
    Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation.
    J Ocul Pharmacol Ther. 2024;40:297-308.
    PubMed     Abstract available
    
    
    
97. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:259-260.
    PubMed    
    
    
    May 2024
98. ANDERSON SG, Meyer D, Decloedt EH
    The Ocular Penetration and Intraocular Pressure Lowering Effect of Topical Acetaminophen in the New Zealand White Rabbit.
    J Ocul Pharmacol Ther. 2024 May 27. doi: 10.1089/jop.2024.0020.
    PubMed     Abstract available
    
    
    
99. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:203.
    PubMed    
    
    
    April 2024
100. GUO M, Liu T, Miao Y, Pan X, et al
     Role of NADPH Oxidase 4 on Dry Eye Syndrome in Mice.
     J Ocul Pharmacol Ther. 2024 Apr 26. doi: 10.1089/jop.2024.0002.
     PubMed     Abstract available
     
     
     
101. NERI P, Perez Y, Agarwal A, Pichi F, et al
     Unraveling the Complexities of Severe Acute Respiratory Syndrome Coronavirus 2: A Comprehensive Ophthalmic and Systemic Perspective.
     J Ocul Pharmacol Ther. 2024 Apr 25. doi: 10.1089/jop.2024.0037.
     PubMed     Abstract available
     
     
     
102. BISEN AC, Srivastava S, Mishra A, Sanap SN, et al
     Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery.
     J Ocul Pharmacol Ther. 2024 Apr 23. doi: 10.1089/jop.2023.0166.
     PubMed     Abstract available
     
     
     
103. ANAM A, Liu C, Tong L, Liu YC, et al
     Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain.
     J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0155.
     PubMed     Abstract available
     
     
     
104. GONZALEZ VH, Uram M, Schupp A, Widmann M, et al
     AG-920 (Articaine) Ophthalmic Solution: A Masked, Active-Controlled Evaluation of Its Local Anesthetic Efficacy and Safety in Pediatric Patients.
     J Ocul Pharmacol Ther. 2024 Apr 22. doi: 10.1089/jop.2023.0187.
     PubMed     Abstract available
     
     
     
105. TRAN HDM, Ha TTX, Tran YH, Coroneo M, et al
     Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
     J Ocul Pharmacol Ther. 2024 Apr 15. doi: 10.1089/jop.2023.0173.
     PubMed     Abstract available
     
     
     
106. HUSAIN S, Obert E, Singh S, Schnabolk G, et al
     Inhibition of HDAC1 and 3 in the Presence of Systemic Inflammation Reduces Retinal Degeneration in a Model of Dry Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024 Apr 12. doi: 10.1089/jop.2023.0163.
     PubMed     Abstract available
     
     
     
107. YADAV KS, Bisen AC, Ishteyaque S, Sharma I, et al
     Solanum nigrum Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model.
     J Ocul Pharmacol Ther. 2024 Apr 11. doi: 10.1089/jop.2023.0089.
     PubMed     Abstract available
     
     
     
108. MISHRA A, Agrawal M, Tripathi A, Bhirud A, et al
     A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
     J Ocul Pharmacol Ther. 2024 Apr 10. doi: 10.1089/jop.2023.0186.
     PubMed     Abstract available
     
     
     
109. DIAS PB, Rodrigues Parchen MDA, Wasilewski D
     Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement.
     J Ocul Pharmacol Ther. 2024 Apr 8. doi: 10.1089/jop.2023.0148.
     PubMed     Abstract available
     
     
     
110. GARWEG JG, Pietzuch M, Mantel I, Ambresin A, et al
     Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".
     J Ocul Pharmacol Ther. 2024;40:199-200.
     PubMed    
     
     
     
111. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:158-159.
     PubMed    
     
     
     
112. WATANABE M, Sato T, Umetsu A, Nishikiori N, et al
     Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor-beta2 or Dexamethasone.
     J Ocul Pharmacol Ther. 2024;40:189-196.
     PubMed     Abstract available
     
     
     
113. GAO J, Wang Y, Han R, Li J, et al
     Elevated KDM4D Expression in Pterygium: Impact and Potential Inhibition by Lycium Barbarum Polysaccharide.
     J Ocul Pharmacol Ther. 2024;40:181-188.
     PubMed     Abstract available
     
     
     March 2024
114. CHENG Y, Liu G
     Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model.
     J Ocul Pharmacol Ther. 2024 Mar 28. doi: 10.1089/jop.2023.0154.
     PubMed     Abstract available
     
     
     
115. CID-BERTOMEU P, Vilaltella M, Martinez M, Mir M, et al
     Topical Insulin for Ocular Surface Disease.
     J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2024.0016.
     PubMed     Abstract available
     
     
     
116. MURAKAMI Y, Imaizumi T, Hashizume K, Tezuka Y, et al
     Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.
     J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2023.0141.
     PubMed     Abstract available
     
     
     
117. YILMAZ OF, Sarmis A
     Relationship Between Conjunctival Corynebacterium and 5% Sheep Blood Agar.
     J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0010.
     PubMed    
     
     
     
118. COLUCCIELLO M
     Steroid/AntiVascular Endothelial Growth Factor Combination Therapy for Neovascular Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0013.
     PubMed    
     
     
     
119. LEE JH, Kim JH
     Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2024;40:136-143.
     PubMed     Abstract available
     
     
     
120. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2024;40:109-110.
     PubMed    
     
     
     
121. FIGUS M, Giansanti F, Villani E, Alio JL, et al
     Chloroprocaine 3% Gel as a Novel Ocular Topical Anesthetic: Results from a Multicenter, Randomized Clinical Trial in Patients Undergoing Cataract Surgery.
     J Ocul Pharmacol Ther. 2024;40:117-125.
     PubMed     Abstract available
     
     
     February 2024
122. RUAN M, Wang R, He Y
     Novel Drug Delivery Systems for the Management of Fungal Keratitis.
     J Ocul Pharmacol Ther. 2024 Feb 23. doi: 10.1089/jop.2023.0161.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.